In push to expand its CAR-T therapies to US, China biotech Oricell raises additional $45M

28 Feb 2023
endpts.com
Cell TherapyImmunotherapyPhase 1Clinical Result
Shanghai biotech Oricell has raised an additional $45 million to bankroll its preclinical and early-stage cancer cell therapies, it announced Tuesday morning. Following a showing at ASCO last year with a GPRC5D-directed CAR-T therapy for multiple myeloma, Oricell raised a $120 million Series B in July. The latest raise is an extension of that round, and was led by RTW Investments and Qatar Investment Authority, followed by existing investors Qiming Venture Partners and C&D Emerging Industry Equity Investment. The biotech said that newly raised money would primarily be put towards clinical development in the US. Oricell is working on a number of CAR-T therapies and solid tumor antibody candidates. In the Phase I trial presented at ASCO, a group of patients with treatment-resistant multiple myeloma had a 100% overall response rate and 60% stringent complete response to Oricell’s GPRC5D-directed CAR-T. In particular, OricellOricell highlighted a group of five patients who had already received BCMA CAR-T therapy. Two achieved stringent complete response, two had “very good partial response,” and one had a partial response, the company said. And with a median follow-up ranging from 35 to 281 days, all were progression-free at the cutoff date at ASCO. Oricell said it hopes to expand the trial for its GPRC5D-directed CAR-T therapy to the US, where it’s currently in the IND-enabling phase. In addition, OricellOricell has a GPC3-directed CAR-T cell therapy called Ori-C101, which it’s studying in advanced hepatocellular carcinoma.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.